GLP-1 for type 1 diabetes as adjunct — need advice

PeptideChemSF said:

Read four things before the headline number.

Pushing back on PeptideChemSF here. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

SarahChen_PharmD said:

My own curve sits about four points below the published mean and I spent two months assuming that meant something was wrong with me or with my…

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

1. Point estimate (HR/RR/OR) — center of the diamond
2. Confidence interval width — precision of the estimate
3. I² statistic — heterogeneity across studies
4. Individual study weights — are results driven by one large trial?
5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.84 (95% CI 0.68-0.89), I²=57%. This is a robust and consistent effect.

RetaRick_CA said:

I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

RetaRick_CA said:

...regarding the trial evidence...

I think this is an underappreciated point. To expand on it with some data:

A recent meta-analysis of 15 RCTs (n=12,300) found that the trial evidence was associated with a clinically meaningful effect size across diverse patient populations[1].

The NNT was 12, which is comparable to statins for secondary prevention. That's a strong clinical argument for this approach.

Following on from alex_tucson — and this may be the naive question:

Was that from a primary source or from a summary of one?

Reporting back.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.